Make faster, better drug development decisions
Antibody-drug conjugates (ADCs) are inherently complex molecules and the space has seen the number of molecules with unique linker, payload, antibody, and conjugation methods expand significantly over the past three years. This creates a significant challenge when it comes to understanding how to create an ADC with the technology combination that is most likely to result in market approval.
The diverse number of technologies presents significant challenges in searching, tracking, and benchmarking. Beacon ADC covers these challenges in one solution so that you can focus your time on what matters.
Beacon ADC
Maximize Your Data With the Most Complete Trial, Drug, and Commercial Database for ADCs
What We Cover
Beacon ADC is a manually curated database solution that includes clinical trial and drug records for preclinical, active, approved and discontinued:
- ADC (Antibody Drug Conjugates)
- Immunotoxins
- SMDCs (Small Molecule Drug Conjugates)
- Radioimmunoconjugates
- Ligand Conjugated Nanoparticles
- Liposomal Drug Conjugate and other comparable modalities
Commercial intelligence data expansion: Gain unparalleled access to in-depth company profiles and the latest commercial deals. Monitor your competitors and opportunities as well as benchmark deals and evaluate potential partners. Learn more by downloading the factsheet
How Beacon Helps
Here are a few example use cases that have benefitted our clients in accelerating their ADC development programs:
- Benchmark drug development and clinical trial strategies against competitors.
- Getting an in-depth competitive landscape overview of the competitors and their assets in the clinic.
- Drastically reduce manual research time with our database solution which allows users to rapidly assemble data for analysis on targets, payloads and much more.
- Identify new players and new assets in entering the clinic and monitor their progress.
How Beacon ADC Works
Search the trial and drug landscape by linker, payload and target alongside 20 other search criteria including disease, line of therapy, biomarker, sponsor etc. Instantly extract the data points you need to conduct more complex analyses.
Our unique Milestones filter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely and exhaustive single-drug timeline allowing you to benchmark progress in the ADC space.
How We Target the Data
We house all publicly available sources of data updated within 24 – 48 hours of publication proactively. Our sources cover (but are not limited to):
- Clinical Trials Registries
- Scientific Journals and Publications
- Company Reports and Presentations
- Press Releases
- Conference Reports and Abstracts
- Government and Regulatory Organizations
- Newspapers and other media
- Patents
Related Content
H1 2024 ADC Landscape Review
Webinar – Novel Drug Conjugates and Clinical Success: An In-Depth Analysis of Emerging ADCs
Unlocking the Potential of Bispecific ADCs
What Our Customers Say
“I look forward to using Beacon. It saves me hours of trawling through false positive results to my searches.”
Head of Competitive Intelligence
Multinational Pharmaceutical Company
Our ADC Expert
Yu-Shin is the lead research analyst for ADC-related drugs and trials in the Beacon team.
Sign up to her weekly newsletter with the latest ADC landscape insights and updates with data from Beacon ADC.
Other Beacon Solutions
Covering all Bi- and Multi-Specific Antibodies, Antibody Fragments, Augmented Antibodies and more
Beacon Cancer Vaccine provides the solution you need to master the prophylactic and therapeutic cancer vaccines field.
Covering all Immune Checkpoint Combination Trials and Immune Checkpoint Modulators in development across 27 different checkpoint targets
Beacon Cell Therapy covers genetically and non-genetically engineered allogeneic and autologous cell-based therapies across all disease indications
Covering all cytokines and drugs that target a cytokine or its immediate receptor belonging to the Interleukins, Interferons, Colony-stimulating factors, Transforming growth factor β, Tumour necrosis factor and Chemokines families.
Beacon DDR steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the DDR field.
From gene-editing technologies, novel delivery systems, and a variety of genetic materials being used- Beacon Gene Therapy steps into the field to give drug developers a precise and detailed view of how the gene therapy landscape looks.
Covering all therapeutics aimed at treating immune-mediated diseases – Beacon Immune Tolerance provides drug developers with detailed views of the expanding immune tolerance landscape.
Covering all pharmaceutical grade microbiome-based therapeutics across all disease indications – Beacon Microbiome provides drug developers with detailed views of the expanding microbiome landscape.
From capturing viral family and strains to understanding any genetic modifications – Beacon Oncolytic Viruses steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the Oncolytic Virus field.
Covering Oligonucleotide-based, mRNA-Based, Ribozyme, and gRNA-Mediated Gene Editing therapies, as well as RNA-Targeted Small Molecules – Beacon RNA covers all disease indications and many modalities to provide a detailed landscape of the RNA space.
Beacon TPD provides the solution you need to master the targeted protein degradation field.
Any Questions? Contact Us
To learn how Beacon ADC can align, optimize, and maximize your trial, drug, and commercial intelligence, get in touch with our sales team.
About Beacon
Beacon is a world-leading data analysis subscription platform for drug, trial, and commercial intelligence. With unrivaled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information that gives you the confidence to progress your targeted drug therapies to patients.
